The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has
revolutionized the treatment of solid tumor malignancies. In breast cancer, the most robust …

Breast cancer has historically been a disease for which immunotherapy was largely
unavailable. Recently, the use of immune checkpoint inhibitors (ICIs) in combination with …

Abstract Purpose of Review To critically review the existing evidence on immune checkpoint
inhibitors (ICIs) in early-stage and metastatic breast cancer and discuss emerging strategies …

Immunotherapy is currently approved for a subset of patients diagnosed with advanced triple
negative breast cancer (TNBC), based on the phase III randomized controlled trial …

Breast cancer is a major killer of women's health worldwide. While breast cancer is thought
to have lower immunogenicity compared with other solid tumors, combination therapy is …

Immune checkpoint inhibitors (ICIs) have led to durable clinical remissions in many
metastatic cancers. However, the single-agent efficacy of ICIs in breast cancer is low …

Immunotherapy comprises a promising new era in cancer therapy. Immune checkpoint
inhibitors targeting either the programmed death (PD)-1 receptor or its ligand PD-L1 were …

Recent progress in immunobiology has led the way to successful host immunity
enhancement against breast cancer. In triple-negative breast cancer, the combination of …

Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer
strategy. Several lines of evidence support the study of immunotherapy in triple-negative …

Over the past 10 years, immunotherapy with immune checkpoint inhibitors has
revolutionized the management of various cancers. However, immunotherapy in breast …